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VCF placement, which may be a reliable, rapid, and cost-
effective option.
METHODS
The project protocol was approved by the
Institutional Review Board. All subjects were screened for
inclusion/exclusion criteria (Table I),8,9 and informed
consent was obtained.
Twenty-six patients were enrolled between October
1998 and May 2000. Information about each patient was
gathered prospectively according to recommended assess-
ment guidelines for venous disease and vena caval filter
placement.9,10 Demographics, medical history, indications
for filter placement, risk factors for deep venous thrombo-
sis (DVT) and location and extent of DVT (Tables II and
III) were documented on comprehensive data sheets.
After draping the patient, we performed “premeasure-
ment” of the IVUS catheter (monorail configuration) to
the precise length of the over-the-wire percutaneous
femoral Greenfield deployment device with a Steri-Strip
(3M, St Paul, Minn) (Fig 1).5,8 This premeasurement per-
mits placement of external markers during IVUS pullback
assessment, which will directly correlate with the subse-
quent deployment device length and position. A single
groin puncture method was used in all patients. After
femoral vein cannulation, a J-tipped guidewire was passed
into the central venous circulation and then exchanged for
a floppy-tipped super stiff wire (through a 5F-angled guide-
Vena cava filters (VCFs) have been used since the late
1960s for the prevention and treatment of venous throm-
boembolism. Initially, inferior vena cava (IVC) filters were
placed in the operating room through surgical cutdowns.
Techniques have evolved such that filters are now usually
placed in the operating room or angiography suite with
fluoroscopic guidance. Recently, some institutions have
attempted to make the insertion of VCFs safer and more
economical by performing the procedure at the patient’s
bedside.1,2
Other techniques take advantage of the portability and
reliability of duplex and intravascular ultrasound (IVUS).3-5
Bedside IVUS allows for detailed evaluation of the IVC
without the use of radiocontrast agents6,7 and avoids
transporting critically ill patients. This report describes an
initial experience with the use of bedside IVUS-directed
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Objective: The purpose of this study was to report a feasibility trial approved by the Institutional Review Board for
insertion of inferior vena cava (IVC) filters with intravascular ultrasound (IVUS) guidance in the intensive care unit.
Methods: Between October 1998 and May 2000, 26 patients (15 men, 11 women; age range, 22-86 years; mean, 55
years) were enrolled. Eight patients (31%) underwent prophylactic filter placement, and 18 patients (69%) had venous
thromboembolism (deep venous thrombosis = 16, pulmonary embolism = 2) with contraindications to anticoagulation.
A single groin puncture was used for IVUS and filter placement. Location of major branch veins, thrombosis, and caval
diameter were readily demonstrated without the use of radiocontrast agents. Mapping of the IVC permitted assessment
of ideal filter location. Postprocedure radiographs (23 of 26) were obtained to document filter position. Seventeen of
26 had follow-up lower extremity duplex studies.
Results: Twenty-four (92%) of 26 patients underwent successful filter deployment. The two other patients had filters
subsequently placed by means of traditional fluoroscopic techniques. One femoral vein insertion site thrombosis
resolved after a month. One patient experienced symptomatic caval thrombosis thought to be caused by thrombus trap-
ping 55 days after the procedure. No pulmonary emboli occurred after filter placement. One patient’s death was unre-
lated to vena cava filter placement. The hospital charge for bedside filters was $3623 compared with $4165 (P = .281)
for fluoroscopic placement.
Conclusion: Bedside insertion of an IVC filter with IVUS guidance is feasible and may be an effective alternative in the
intensive care unit. No additional costs were incurred in this small series. Protocol refinements should reduce the inci-
dence of complications. The results of this study support the need for further evaluation comparing it with standard
techniques. (J Vasc Surg 2001;34:21-6.)
catheter). The monorail IVUS catheter was then passed
over the super stiff wire, up to the level of the right atrium.
Venous anatomy was examined with the pullback tech-
nique, and the landing zone (Fig 2) between the renal veins
and iliac vein confluence was marked on the immobilized
drape with Steri-Strips, a long one for the renal veins and a
short one for the iliac confluence. This was confirmed with
a second pullback run before removal of the IVUS catheter
with particular attention to guidewire position appearing
directly adjacent to the IVUS catheter. The 8F sheath was
removed, the tract was serially dilated, and the deployment
sheath was inserted. The VCF was then deployed in the
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Table I. Inclusion and exclusion criteria for the 26 study patients
Inclusion criteria (at least one from each of the two following categories [I and II])
I. Indications for VCF
Documented thromboembolism and anticoagulation contraindicated 12 (46%)
High risk for thromboembolism and anticoagulation contraindicated 10 (38%)
Complication of anticoagulation
Failure (thrombus extension or PE) 0
Hemorrhage: major or minor 1 (4%)
Thrombocytopenia 0
Skin necrosis 0
Drug reaction 0
Poor compliance 0
Prophylaxis: no thromboembolic disease 0
Prophylaxis with thromboembolism in addition to anticoagulation 2 (8%)
Failure of previous device or recurrent PE 1 (4%)
In association with another procedure: thrombectomy, embolectomy, or lytic therapy
II. Relative contraindications to conventional filter placement
Relative contraindication to transporting patient out of the ICU 26 (100%)
Mechanical ventilation
External CSF drain
Unstable spine
Infectious isolation
Continuous venovenous hemofiltration
Hemodynamic instability/vasoactive drips
Multiple invasive catheters
Active resuscitation
Hypothermia
RV dysfunction, potentially exacerbated by IV contrast 0
Renal insufficiency or contrast allergy 2 (8%)
Exclusion criteria
Inability to obtain informed consent for participation in the study
Absence of patent IVC or iliofemoral vein
Known IVC diameter > 28 mm 
Known congenital IVC abnormalities: duplicated, left-sided, low renal vein
Active bilateral groin infection
Previous filter placement
OLT within 2 weeks
CSF, Cerebrospinal fluid; ICU, intensive care unit; IV, intravenous; IVC, inferior vena cava; OLT, orthotoptic liver transplant; PE, pulmonary embolism;
RV, right ventricle; VCF, vena cava filter.
Table II. Risk factors for thromboembolism
History of DVT 7 (27%)
Immobilization
> 3 d 17 (65%)
Acute paraplegia/stroke 6 (23%)
Postoperative status 16 (62%)
Age 
> 70 y 4 (8%)
> 40/< 70 y 17 (65%)
Malignancy 8 (31%)
Cardiac disease 6 (23%)
Trauma or limb fracture 7 (27%)
Prothrombotic state 0
Hormonal therapy 0
Pregnancy/postpartum 0
Obesity 2 (8%)
Smoking 5 (19%)
Table III. Study patient DVTs
Present/absent 16/10 (62%/38%)
PE w/o documented DVT 2 (8%)
DVT side
Right 8 (50%)
Left 4 (25%)
Bilateral 4 (25%)
DVT position
Iliac 4 (25%)
Femoral 9 (56%)
Popliteal 4 (25%)
Tibial-soleal 2 (13%)
Superficial 0 (
cephalad end of the landing zone after removal of the
guidewire. The guidewire was removed before deployment
to avoid entrapment of the wire in the limbs of the filter,
which would be difficult to address without the aid of fluo-
roscopy. Gentle pressure was applied until the feet could be
raised to obtain hemostasis.
An anteroposterior abdominal radiograph was
obtained primarily to assess filter location. VCF tilt and
limb asymmetry were recorded as incidental findings if
seen on this single view; lateral films were not obtained.
Postprocedure duplex scans were performed at approxi-
mately 2 weeks after VCF insertion to assess for insertion
site and caval patency. Adverse events, including recurrent
thromboembolism and other complications, were
recorded prospectively.
Costs and charges were compared with those of a
cohort of patients who underwent conventional fluoro-
scopic VCF placement in the angiography suite during the
same time period. Charges included in the retrospective
analysis were (1) preprocedure studies; (2) venography
and contrast; (3) supervision, interpretation, and catheter-
ization fees; (4) medications used during the procedure;
(5) charges for the VCF supplies; and (6) immediate post-
procedure confirmational studies. The cost analysis
excluded physician fees.
RESULTS
Twenty-four (92%) of 26 patients (15 men, 11 women;
age range, 22-86 years; mean, 55 years) underwent suc-
cessful placement of the VCF in the infrarenal IVC. One
patient had caudal placement of the filter in the left com-
mon iliac vein because of operator error in mistaking the
caval confluence marker as the renal vein marker. This
prompted a protocol change to two distinct markers. This
patient then underwent an uneventful second VCF place-
ment in the interventional suite; a right internal jugular
approach was used. VCF placement with IVUS was
aborted in another patient who had recently undergone an
orthotopic liver transplant (OLT). We studied only one
patient with a recent OLT, stopping because of the trans-
plant surgeon’s concern about disrupting the venous anas-
tomosis; the anatomy was not sufficiently clear to ensure
safe deployment of the VCF. Conventional VCF placement
was accomplished without incident. Subsequently, recent
OLT was added as an exclusion criterion.
Procedure time was not recorded in this pilot study,
but generally took 10 to 20 minutes after venous access
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was obtained, totaling 40 to 50 minutes including drap-
ing, prepping, and documentation. Immediate confirma-
tion of VCF placement with a portable abdominal
radiograph was obtained in 23 of 26 patients. Only one
patient had significant tilt greater than 13 degrees. The
distance from the insertion site at the inguinal crease to
the Steri-Strip markers for the renal veins and iliac vein
confluence was recorded in latter half of the study (renal
veins 52 ± 4.2 cm [range, 45-56 cm]; iliac confluence 60
± 4.3 cm [range, 52-65 cm]). Care was taken to record
these measurements during pullback of the IVUS probe to
avoid significant length discrepancies, because the IVUS
catheter tends to bow within the vein when advanced.
Seventeen patients (65%) underwent lower extremity
duplex scans in follow-up. One patient experienced an
acute insertion site DVT within the first week that com-
pletely resolved by 29 days after VCF placement. Another
patient presented with bilateral lower extremity edema and
cyanosis 56 days after the procedure. A duplex scan
showed an acute IVC occlusion, which appeared to be
caused by trapped thrombus. This patient was treated with
warfarin sodium (Coumadin) for 6 months, with the filter
recanalizing 5 months after initial diagnosis. The alterna-
tive, thrombolysis, was not used.
No other major adverse events related to VCF inser-
tion occurred within 30 days. No clinical pulmonary
emboli have occurred. One death due to respiratory fail-
ure occurred on postprocedure day 9 in a patient with a
history of a right pneumonectomy who underwent a left
thoracotomy for spinal fusion.
Hospital charges for eight patients undergoing IVUS
VCF placement were compared with those of eleven con-
trols (5 men, 6 women; age range, 37-84 years; mean, 61
years) undergoing conventional VCF placement during the
same time period (Table IV). The difference in total charges
between the two groups did not reach statistical significance
because of the low sample size and high variability among
the individual patient charges. However, the estimated total
difference in dollars saved was $14,092, if this savings is
extended to all 26 patients. Cost analysis (excluding physi-
cian services) showed an even greater potential for savings,
because the cost for an individual IVUS procedure was
$880 less than conventional placement.
DISCUSSION
New techniques for VCF placement have been devel-
oped recently in an effort to contain costs, reduce place-
Table IV. Charge analysis*
Total charges Mean ± SD P value†
IVUS-placed VCFs (n = 8) 3623 ± 935
.281Conventional IR/OR–placed VCFs (n = 11) 4165 ± 1121
*All number in dollars.
†Calculated with independent samples t test.
IR, Interventional radiology; IVUS, intravascular ultrasound; OR, operating room; VCF, vena cava filter.
ment time, avoid nephrotoxic contrast media, and mini-
mize transportation risks in critically ill patients.1-5 With
the conventional approach, one must take into account
the delay of waiting for an available procedure room as
well as the difficulties and potential hazards such as
hypothermia, catheter dislodgement, and hemodynamic
instability encountered when transporting the patient out-
side of the intensive care unit. IVUS-directed VCF place-
ment may reduce these risks.
Transabdominal ultrasound-directed VCF placement
is another bedside alternative but has disadvantages.
Fourteen percent of patients in one study were not candi-
dates for this technique4 because of poor visualization
related to obesity and intraluminal bowel gas. In our expe-
rience, body habitus has not been a problem in accurately
deploying the VCF with IVUS. In fact, we have found it
particularly useful in patients who are obese, have an open
abdomen, and have intra-abdominal packing for hemosta-
sis and pancreatic debridement. We have not encountered
abnormal venous anatomy in our small series, but if we
had, we would have left the 8F access sheath in the groin
and transported the patient to interventional radiology or
to the operating room for conventional deployment.
With IVUS, interesting phenomena have been recog-
nized that may become clinically significant. The presence
of “smoke” (indicating sluggish venous flow) may serve as
a marker for caval thrombosis, analogous to left atrial
smoke and arterial thromboembolism. Real-time imaging
of spontaneously breathing patients demonstrates the
shape changes and timing of caval distortion and collapse,
which may contribute to limb asymmetry. These findings
are missed or obscured during venography with radiocon-
trast, where the injection itself artifactually distends the
venous system. It may be useful to deploy VCFs during a
Valsalva maneuver when the cava assumes a cylindrical
shape in patients with adequate intravascular volume.
Complications associated with IVUS-directed place-
ment are comparable to the complication rate seen with
conventional VCF placement. Only one IVC occlusion
(4%) occurred with no patient experiencing a pulmonary
embolism (PE), consistent with the reported 95% to 97%
patency rate of VCFs.11,12 All control patients had accu-
rate VCF placement, with radiographic confirmation at
the time of the procedure, although the literature reports
a misplacement rate of 7%.11 One IVUS-placed VCF (4%)
was misplaced in an unintended vessel. This misplacement
should occur less often with our subsequent protocol
modification. Ideally, an IVUS catheter could be mounted
coaxially on a VCF deployment system to virtually elimi-
nate this risk. One patient (4%) experienced thrombosis of
the femoral vein at the insertion site, compared with about
3% of patients in two large conventional technique stud-
ies.12,13
Many variations of the technique have been consid-
ered. Use of the contralateral groin for placement of the
VCF under direct IVUS guidance, then inspection of the
final filter position immediately after deployment is one
alternative. The disadvantages are the need for two access
sites and the potential for entrapment of the IVUS probe
in the deployed filter. Use of the right internal jugular vein
for access is a variant not used in this study because of fear
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Fig 1. Premeasurement. IVUS catheter is placed alongside VCF
deployment device, and a Steri-Strip is placed on IVUS catheter
the precise length of the device away from tip of IVUS probe.
Fig 2. Schematic depiction of “landing zone” between long and
short Steri-Strip, corresponding to length of IVC between renal
vein confluence and iliac bifurcation, respectively. Steri-Strips are
used as markers on the immobilized drapes within which VCF will
be placed.
of coiling of the guidewires in the right atrium and subse-
quent cardiac injury when passing the deployment sheath.
Other filters have been studied, but the marriage of the
over-the-wire Greenfield filter and pullback over the super
stiff wire provides reliably small length discrepancies. To
confirm this, we performed several IVUS-guided place-
ments with backup fluoroscopy before this bedside study.5
In conclusion, IVUS-directed VCF placement is a fea-
sible alternative to conventional fluoroscopic and transab-
dominal ultrasound-directed techniques. It has some
limitations but also several potential advantages. This ini-
tial trial suggests comparable safety and accuracy without
increased costs. Therefore, this technique deserves further
evaluation in a larger series in which it is compared with
standard techniques.
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Dr Patrick O’Hara (Cleveland, Ohio). Thanks for a nice pre-
sentation. I was going to take the prerogative just to ask one
quick question from my own perspective. I know that you use the
monorail IVUS system to do these measurements, and I know the
couple of times I have used this the catheter will sometimes bow
around the guidewire. You can pick that up when you are under
fluoroscopy, but if you are doing it like this and the catheter bows
on the guidewire, it seems that sometimes you might measure the
distance longer than it really is. I wonder, does that give you a
tendency to place the filter further in than you would like to?
Dr James Ebaugh. The first eight or nine patients before this
trial were performed with fluoroscopy in the operating room, not
including the patients in this series. It was noted that with the
pullback technique over the superstiff wire, the size discrepancy
was only approximately 1 cm. When using it only on the pullback
do we measure the distance from the inguinal crease to the land-
ing zone. 
Dr Lazar Greenfield (Ann Arbor, Mich). My apologies for
standing up again, but the authors deserve a lot of credit for this
approach since the contribution is not only the use of intravascu-
lar ultrasound but the ability to use it through a single puncture
since the previous efforts had been with either contralateral or a
second puncture required to have the control imaging at the same
time that the insertion device was in place. I have a couple of
questions for you. 
First, with the use of intravascular ultrasound, do you think
that you would be able to identify a duplicated vena cava? One of
the advantages of the external studies is that certain vena caval
anomalies can be readily identified. This information can then be
taken into consideration when deciding where to place the filter.
Second, in the positioning you would on occasion have a
need to place the filter suprarenal as well, and I wonder if you
would use a similar pattern for inserting there or what your supe-
rior landmark would be for the suprarenal vena caval insertion, for
example, in a pregnant patient.
You did not identify any thrombus at any time, which I think
is fortunate, and I wonder if you would be willing either to go in
parallel if you had thrombus on both sides or to make some other
approach, perhaps ultrasound from the jugular approach, were
you to identify thrombus in both iliac systems. Thank you.
Dr Ebaugh. With regard to the first question, we did not
encounter any vena cava anomalies, and if there were an IVC
anomaly known prior to the placement, we would recommend a
conventional approach. If we had seen significant size discrepan-
cies between the suprarenal and infrarenal IVC or major branches
in addition to or superior to the iliac vein bifurcation, we would
consider this to be an anomalous IVC, but none were encoun-
tered in this study.
Regarding the second question, we actually did not consider
placing a suprarenal filter for any of the IRB-approved study
patients. None of the patients were pregnant, and we did not con-
sider any landmarks to be used for deployment at this location. 
As for the third question, ipsilateral thrombus at the site of
the procedure was considered an exclusion criteria for the study.
Dr Donald Jacobs (St Louis, Mo). I have three questions.
The first one relates to the changes in the cava and the iliac sys-
tem between the shape that you have when the relatively soft
IVUS catheter is through there and a Greenfield delivery system.
What kind of tolerance do you have for the changes in the
anatomy that occur with the different devices when you are imag-
ing versus when you are delivering?
The second question is a practical one. Right now, the
catheter that you described has been recalled, and we are all wait-
ing for that. Have you used alternative imaging or the Endosonics
device to place these?
The third question relates to your charges or the cost with
the study. Regarding the two patients who had to have subse-
quent fluoroscopic placement, were the charges for those proce-
dures included in the cost for this?
Dr Ebaugh. As for the different devices, most were Greenfield
DISCUSSION
filters. A Vena Tech filter was used in a couple of instances. We
found that the Greenfield was a good alternative to use for this
technique because it consistently gave small length discrepancies
with the pullback technique over the superstiff wire, as I referred
to earlier.
As for the recalled IVUS catheter, we are in touch with the rep-
resentatives, but they actually do not have any news for us either.
As for the cost, you have a good point that if you take into
account the two patients who did have conventional placement
there would only be a $6000 total estimated savings, but we still
think that the charge difference per patient is significant. 
Dr Mark Mattos (Springfield, Ill). Thanks for a nice presen-
tation. I have a comment and a single question. At times, when I
have used IVUS, bowing of the catheter and the guidewire has
made length measurements at times problematic even under flu-
oroscopy. How have you dealt with this problem at the bedside?
Have you run into problems of overestimating length and there-
fore misplacing the filter?
Dr Ebaugh. Eight or nine filters were placed in the operating
room using both IVUS and fluoroscopic guidance prior to this
bedside study. It was noted that with the pullback technique over
the superstiff wire that the size discrepancy was only approxi-
mately 1 cm or so. Only using it on the pullback do we measure
the distance from the inguinal crease to the landing zone.
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